ESLA
Price
$0.79Alerts
Change
+$0.04 (+5.33%)
Updated
Nov 11 closing price
Capitalization
16.32M
21 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$3.59Alerts
Change
+$0.04 (+1.13%)
Updated
Nov 11 closing price
Capitalization
1.89B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ESLA vs RXRX

ESLA vs RXRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ESLA vs. RXRX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESLA is a Hold and RXRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ESLA with price predictions
Nov 10, 2026

ESLA in +99.09% Uptrend, advancing for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ESLA advanced for three days, in 124 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 71 cases where ESLA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.

ESLA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ESLA crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The 10-day RSI Indicator for ESLA moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ESLA as a result. In 67 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.

The Moving Average Convergence Divergence Histogram (MACD) for ESLA turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 29 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

ESLA broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ESLA entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.197) is normal, around the industry mean (3.498). P/E Ratio (-1.501) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ESLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RXRX with price predictions
Nov 10, 2026

RXRX's Stochastic Oscillator is staying in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +8.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 77 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

RXRX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for RXRX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.498). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ESLARXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
51%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
58%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ESLA: $0.75 vs. RXRX: $3.55)
Brand notoriety: ESLA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ESLA: 168% vs. RXRX: 75%
Market capitalization -- ESLA: $16.32M vs. RXRX: $1.89B
ESLA [@Biotechnology] is valued at $16.32M. RXRX’s [@Biotechnology] market capitalization is $1.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESLA’s FA Score shows that 2 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).

  • ESLA’s FA Score: 2 green, 3 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ESLA is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 3 bullish TA indicator(s).

  • ESLA’s TA Score: 4 bullish, 6 bearish.
  • RXRX’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ESLA is a better buy in the short-term than RXRX.

Price Growth

ESLA (@Biotechnology) experienced а +78.76% price change this week, while RXRX (@Biotechnology) price change was -3.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ESLA is expected to report earnings on Dec 02, 2026.

RXRX is expected to report earnings on Mar 03, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and DRUG have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
+45.40%
DRUG - ESLA
28%
Poorly correlated
-6.22%
KPTI - ESLA
27%
Poorly correlated
-56.50%
PRLD - ESLA
25%
Poorly correlated
N/A
RXRX - ESLA
24%
Poorly correlated
-6.70%
HUMA - ESLA
23%
Poorly correlated
+29.61%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-6.70%
CRSP - RXRX
65%
Loosely correlated
-9.77%
PRME - RXRX
62%
Loosely correlated
-9.30%
ABSI - RXRX
60%
Loosely correlated
-7.69%
BEAM - RXRX
60%
Loosely correlated
-6.92%
DNA - RXRX
57%
Loosely correlated
-2.91%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BAC50.680.13
+0.26%
Bank of America Corp
FR54.960.03
+0.05%
First Industrial Realty Trust
CCEL4.87-0.05
-0.92%
Cryo-Cell International
SCL66.77-1.32
-1.94%
Stepan Co
OFIX7.12-0.78
-9.87%
Orthofix Medical